Navigation Links
Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer

LAIYANG, China, July 1 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) (the "Company" or "Jiangbo"), today announced the appointment of Mr. Linxian Jin, a pharmaceutical industry veteran in China, as the Company's Chief Executive Officer (CEO) effective July 1, 2010. As part of an effort to continue to strengthen the senior management team, Mr. Jin will take over the role of CEO from the Company's Chairman, Mr. Wubo Cao, who resigned on June 29, 2010. Mr. Cao will continue his role as Chairman of the Company's Board.

With 20 years working experience in the pharmaceutical industry, Mr. Jin brings with him a wealth of knowledge and experience in production management, cost control, material management, quality control, safety and environmental management, marketing and sales. He also has significant experience with the Chinese, European Union and U.S. GMP certification.

Mr. Jin joined Laiyang Jiangbo Pharmaceuticals, Inc., the wholly owned subsidiary of the Company, as Deputy General Manager of Production Technology in April 2008. Previously, he had been the General Manager of Shandong Luxi Pharmacy Co., Ltd and Deputy General Manager of Shandong Quancheng Pharmaceutical Co., Ltd. From October 2000 to June 2006, Mr. Jin served as Deputy General Manager with Zibo Hualong Pharmaceutical Co., Ltd. and Linuo Group Jinan Yongning Pharmaceutical Co., Ltd. He began his career in 1990 with Shandong Zaozhuang First Pharmaceutical Factory, where he held positions of increasing responsibility including as the Head of Quality Inspection Department, Production Manager, Marketing Manager, and Assistant to General Manager during his ten-year tenure. Mr. Jin holds a bachelor degree with a major in Chemical Pharmaceutical from East China University of Science and Technology.

"I am delighted to join Jiangbo. I believe that Jiangbo is a company with significant growth momentum and a promising future in China's rapidly growing pharmaceutical industry. I congratulate Mr. Cao and the entire team on the achievement of a significant milestone in Jiangbo's history with the listing on the NASDAQ Global Market," said Mr. Jin. "Together with the rest of Jiangbo's management team, I plan to work hard to better define and execute a strategic plan that maximizes Jiangbo's growth potential and returns value to our shareholders."

Mr. Cao, Chairman of Jiangbo's Board, said, "On behalf of the Board, I welcome Mr. Linxian Jin as the new CEO of Jiangbo at a critical turning point in the Company's development when we require a deeper senior management team to achieve our strategic objectives. Mr. Jing brings considerable experience and leadership to Jiangbo and I believe that he is well-qualified to guide the Company through the next chapter of its growth. We both share a common belief in this Company's potential to continue to capitalize on its strong position in China's large pharmaceutical market."

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( ).

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to execute its strategic plan. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-903-9378 x2

    CCG Investor Relations
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
2. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
3. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
4. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
5. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
6. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
7. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
8. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
9. Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair
10. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
11. Vanda Pharmaceuticals Adds Former U.S. Surgeon General, Steven Galson, to its Board of Directors
Post Your Comments:
(Date:11/24/2015)... , Nueva York , 24 ... Devices (ABD), fabricante del Avery Breathing Pacemaker System, ... Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... El doctor Jonzon es un fisiólogo y ...
(Date:11/24/2015)...  DILON Diagnostics and GE Healthcare are pleased to ... to distribute GE,s Discovery NM750b Molecular Breast Imaging system ... distribution agreement will provide Dilon,s experienced distribution network access ... is considered an initial step in an ongoing exploration ... and their patients. --> ...
(Date:11/24/2015)... -- Sectra (STO: SECT B) announces that ... multi-year agreement to deploy Breast Imaging PACS in ... the Breast Center a future-proof platform capable of expanding with ... announces that Breast Center of Acadiana has entered ... PACS in its two freestanding imaging centers. This investment will ...
Breaking Medicine Technology:
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), ... opening of a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The ... new and different way. The location is scheduled to operate through Dec. 24. , ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cold Shoulder , LLC launched their Pro Vest, the latest ... hit their goal of $20,000 in under 10 hours. , The campaign, ... PRO Weight Loss Vest to the market. , The PRO Vest provides consumers with a ...
(Date:11/24/2015)... Baltimore, M.D. (PRWEB) , ... November 24, 2015 ... ... a new award for its exceptional customer service: the TrustDale certification. The award ... experience. The Baltimore stone honing , tile and grout, and hard surface ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Kevin Day, local family chiropractor ... stress less this holiday season. During the Indiana winter months, Vitamin D deficiency ... the team at AlignLife want to help provide the tools needed to combat it ...
Breaking Medicine News(10 mins):